BAY 1158061
Alternative Names: Anti-prolactin receptor monoclonal antibody - Bayer/Hope Medicine; BAY1158061; HMI-115Latest Information Update: 25 Oct 2024
Price :
$50 *
At a glance
- Originator Bayer
- Developer Bayer; Hope Medicine
- Class Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Prolactin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alopecia; Endometriosis
Most Recent Events
- 24 Oct 2024 BAY 1158061 receives Breakthrough Therapy status for Endometriosis in China
- 24 Oct 2024 Hope medicine plans to hold End-of-Phase 2 meetings with FDA, NMPA and other regulatory authorities
- 24 Oct 2024 Efficacy and adverse events data from a phase II trial in Endometriosis released by Hope Medicine